Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients

Abstract

Introduction: Fibroblast growth factor 21 (FGF21) is a metabolic regulator with multiple beneficial effects on glucose and lipid homeostasis and insulin sensitivity. Objectives: The aim of this study was to investigate the relation between the serum level of FGF21 with and metabolic syndrome (MS) in kidney transplant recipients. Patients and Methods: We performed a cross-sectional study on 86 stable renal transplant recipients to detect possible relation between serum FGF21 level and MS during October 2014 and Mach 2015. Patients with past history of diabetes mellitus were excluded. Results: There were 43 patients in each group with and without MS. Totally, they were 52 (60.5%) male and 34 (39.5%) female. The mean age of the MS group was significantly higher than that of non-MS group. There was not significant difference between mean serum creatinine level and glomerular filtration rate (GFR) between two groups (P > 0.05). The MS patients had higher weight and body mass index (BMI) (P < 0.05). The prevalence of BMI >25 kg/m2 in MS group was 25 (58.8%) versus non-MS group that only 10 (23.3%) had this condition (P < 0.05). The mean of FGF21 level in MS and non-MS groups was 1.23 ± 0.67 ng/l and 1.18 ± 0.71 ng/l, respectively (P > 0.05). There was not significant difference of serum FGF21 level between MS and non-MS patients (P > 0.05). Conclusion: While the elevated serum FGF21 level was found in subjects with insulin resistant states, however, this study revealed that serum FGF21 levels were not significantly increased in renal transplanted recipients with MS as compared with non-MS group.

Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT

“…FGF21 is a member of FGF family, which induces beneficial effects in multiple organs in an endocrine manner [22]. Increasing clinical studies have demonstrated that circulating FGF21 levels are dramatically increased in patients with various kidney diseases, including chronic kidney disease (CKD) [23,24], kidney transplantation [25,26], ESRD [27], early-stage diabetic kidney disease [28], acute renal dysfunction [29], and long-term peritoneal dialysis [30], indicating that an increase in FGF21 levels above baseline is a stress response to induce renal protection. This hypothesis was confirmed by a subsequent study, which showed that the administration of FGF21 maintained renal function in mice with CKD [31].…”

Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis

“…For details, a China cohort revealed that higher FGF21 levels increased renal function decline in patients undergoing coronary angiography [ 32 ]. Additionally, two studies have found that FGF21 was inversely related to renal function in kidney transplant patients [ 37 , 38 ]. As the limited eligible studies, no further meta-analysis was performed for this part.…”

Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study

“…Since multiple, favorable FGF21 effects on glucose and lipid metabolism and insulin sensitivity have been reported, FGF21 might be a biomarker that influences metabolic syndrome (MetS) and type 2 diabetes (T2DM) pathophysiology. 3 6 It may also be a therapeutic agent for treating diabetes and other obesity-related metabolic disorders.5 FGF21 has also been shown to be a potent metabolic regulator. 5 7 8 9 In addition, research has shown that increased FGF21 levels are associated with MetS in Asian individuals.…”